Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“Can we improve frontline outcomes for patients with high-risk large B-cell lymphoma by adding a bispecific antibody to standard R-CHOP?
Results from arm 1 of the phase 1b/2 EPCORE NHL-2 trial evaluate fixed-duration epcoritamab plus R-CHOP in patients with newly diagnosed LBCL and high-risk International Prognostic Index (IPI) scores of 3–5.
Despite a high-risk population – 89% with stage IV disease and 53% with bulky disease – the combination demonstrated impressive activity:
- Overall response rate: 98%
- Complete response rate: 85%
- MRD negativity: 100% of evaluable patients
- Estimated 2-year PFS: 80%
- Estimated 2-year OS: 87%
After a median follow-up of 44.2 months, median duration of complete response, PFS, and OS had not been reached.
The safety profile included neutropenia (74%), anemia (72%), and cytokine release syndrome (60%). CRS events were predominantly grade 1 – 2, and all resolved.
The most intriguing finding may be the depth of response: all MRD-evaluable patients achieved MRD negativity, alongside high complete response rates and encouraging long-term disease control.
These results suggest that engaging T cells through CD20×CD3 bispecific therapy may strengthen frontline chemoimmunotherapy for patients with high-risk LBCL.
However, this remains a 47-patient, single-arm phase 1b/2 cohort. The ongoing phase 3 evaluation will be essential to determine whether these results translate into improved outcomes over standard frontline therapy.
The question is no longer simply whether bispecific antibodies can work in aggressive lymphoma, but how best to integrate them into frontline treatment.”
Title: Fixed-duration epcoritamab plus R-CHOP for newly diagnosed LBCL with an IPI score of 3 to 5: results from the EPCORE NHL-2 trial
Authors: Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua D. Brody, Daniel Morillo, Kim M. Linton, Sylvia Snauwaert, Michael Roost Clausen, Yasmin H. Karimi, Catherine Thieblemont, Umberto Vitolo, Lori Leslie, Mayur Narkhede, Raul Cordoba, Toshihiko Oki, Monica Wielgos-Bonvallet, Mina Khoshdeli, Yi Hao, Kimberly Archer, Malene Risum, David Belada
You can also read:
